U.S. markets closed
  • S&P 500

    4,070.56
    +10.13 (+0.25%)
     
  • Dow 30

    33,978.08
    +28.67 (+0.08%)
     
  • Nasdaq

    11,621.71
    +109.30 (+0.95%)
     
  • Russell 2000

    1,911.46
    +8.39 (+0.44%)
     
  • Crude Oil

    79.38
    -1.63 (-2.01%)
     
  • Gold

    1,927.60
    -2.40 (-0.12%)
     
  • Silver

    23.73
    -0.30 (-1.23%)
     
  • EUR/USD

    1.0874
    -0.0018 (-0.16%)
     
  • 10-Yr Bond

    3.5180
    +0.0250 (+0.72%)
     
  • GBP/USD

    1.2395
    -0.0012 (-0.10%)
     
  • USD/JPY

    129.8000
    -0.3530 (-0.27%)
     
  • BTC-USD

    23,232.01
    +128.79 (+0.56%)
     
  • CMC Crypto 200

    526.66
    +9.65 (+1.87%)
     
  • FTSE 100

    7,765.15
    +4.04 (+0.05%)
     
  • Nikkei 225

    27,382.56
    +19.81 (+0.07%)
     

Seagen Appoints Sandra M. Swain, M.D., to Board of Directors

BOTHELL, Wash., November 10, 2022--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that Sandra M. Swain, M.D., has been appointed to the company’s Board of Directors. Dr. Swain has more than 30 years of breast cancer clinical research experience. She currently serves as Associate Dean for Research Development and Professor of Medicine at Georgetown University Medical Center and is the Vice President of Genetic Medicine for MedStar Health. She is also on the Conquer Cancer Foundation Board of American Society of Clinical Oncology (ASCO) and chairs the Women Who Conquer Cancer committee.

"We are pleased to welcome Sandra to our Board of Directors given her extensive research and clinical trial experience, especially in HER2-positive metastatic breast cancer," said Felix J. Baker, Ph.D., Chair of the Seagen Board of Directors. "Her success in advancing treatments to address unmet medical needs of patients aligns directly with Seagen’s mission and our efforts to bring important, targeted medicines to cancer patients worldwide."

"As a medical oncologist who has cared for many patients with breast cancer, it is an honor to join the board of a company advancing important medicines that can meaningfully improve patient care," said Dr. Swain. "Seagen is on a great trajectory with four approved medicines, a differentiated and diverse pipeline, leadership in antibody-drug conjugates and a talented team dedicated to patients in need. I look forward to contributing to the Board to support Seagen’s vision of improving the lives of people with cancer."

Prior to her current roles at Georgetown University and MedStar Health, Dr. Swain held roles at the National Cancer Institute, National Institutes of Health, the Washington Cancer Institute at MedStar Washington Hospital Center, and FDA Oncologic Drugs Advisory Committee. She is a fellow of the American College of Physicians and ASCO. Dr. Swain has served on ASCO’s board of directors and is a past president (2012-2013). She has published over 335 articles, including many regarding clinical trials in breast cancer. Dr. Swain holds an M.D. from the University of Florida and a B.A. in Chemistry from the University of North Carolina.

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the trajectory of the company, its pipeline, and its efforts to bring important, targeted medicines to cancer patients worldwide. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the difficulty and uncertainty of pharmaceutical product development, the risk of adverse events or safety signals, the inability to show sufficient activity in clinical trials, the possibility of adverse regulatory actions and the risk that the company’s trajectory may not be as expected. More information about the risks and uncertainties faced by Seagen is contained under the caption "Risk Factors" included in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005265/en/

Contacts

For Media
David Caouette
(310) 430-3476
dcaouette@seagen.com

For Investors
Douglas Maffei, Ph.D.
(425) 527-4881
dmaffei@seagen.com